ADRB2 blockers, such as propranolol and metoprolol, reduce pulmonary inflammatory response in patients with COVID-19 when acute respiratory distress syndrome occurs, suggesting that ADRB2 might be involved in the inflammatory response (28, 29). This evidence concerns the gene ADRB2 and acute respiratory distress syndrome.